162 related articles for article (PubMed ID: 36471278)
1. TG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway.
Xu D; Xu N; Sun L; Yang Z; He M; Li Y
BMC Cancer; 2022 Dec; 22(1):1267. PubMed ID: 36471278
[TBL] [Abstract][Full Text] [Related]
2. Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis.
Shao GL; Wang MC; Fan XL; Zhong L; Ji SF; Sang G; Wang S
Technol Cancer Res Treat; 2018 Jan; 17():1533034617754024. PubMed ID: 29529946
[TBL] [Abstract][Full Text] [Related]
3. NCAPH promotes cell proliferation and inhibits cell apoptosis of bladder cancer cells through MEK/ERK signaling pathway.
Li B; Xiao Q; Shan L; Song Y
Cell Cycle; 2022 Feb; 21(4):427-438. PubMed ID: 34974790
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.
Assi J; Srivastava G; Matta A; Chang MC; Walfish PG; Ralhan R
PLoS One; 2013; 8(9):e74437. PubMed ID: 24058567
[TBL] [Abstract][Full Text] [Related]
5. MiR-96-5p promotes breast cancer migration by activating MEK/ERK signaling.
Qin WY; Feng SC; Sun YQ; Jiang GQ
J Gene Med; 2020 Aug; 22(8):e3188. PubMed ID: 32196830
[TBL] [Abstract][Full Text] [Related]
6. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
7. Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1/STAT3 phosphorylation in ovarian cancer.
Sima LE; Chen S; Cardenas H; Zhao G; Wang Y; Ivan C; Huang H; Zhang B; Matei D
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593619
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of tissue transglutaminase 2 in colon carcinoma.
Fernández-Aceñero MJ; Torres S; Garcia-Palmero I; Díaz Del Arco C; Casal JI
Virchows Arch; 2016 Dec; 469(6):611-619. PubMed ID: 27620315
[TBL] [Abstract][Full Text] [Related]
9. SIRT5 is involved in the proliferation and metastasis of breast cancer by promoting aerobic glycolysis.
He S; Jia Q; Zhou L; Wang Z; Li M
Pathol Res Pract; 2022 Jul; 235():153943. PubMed ID: 35576836
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Transglutaminase 2 in Patients with Solid Tumors: A Meta-analysis.
Gao J; Wang S; Wan H; Lan J; Yan Y; Yin D; Zhou W; Hun S; He Q
Genet Test Mol Biomarkers; 2023 Feb; 27(2):36-43. PubMed ID: 36809173
[No Abstract] [Full Text] [Related]
11. The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2.
Bianchi N; Brugnoli F; Grassilli S; Bourgeois K; Keillor JW; Bergamini CM; Aguiari G; Volinia S; Bertagnolo V
Cells; 2021 Nov; 10(11):. PubMed ID: 34831282
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype.
Chen X; Adhikary G; Shrestha S; Xu W; Keillor JW; Naselsky W; Eckert RL
Mol Cancer Res; 2021 Dec; 19(12):2026-2035. PubMed ID: 34593609
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression.
Chang CC; Zhang C; Zhang Q; Sahin O; Wang H; Xu J; Xiao Y; Zhang J; Rehman SK; Li P; Hung MC; Behbod F; Yu D
Oncotarget; 2016 Jun; 7(23):35270-83. PubMed ID: 27150057
[TBL] [Abstract][Full Text] [Related]
14. Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
Nokin MJ; Bellier J; Durieux F; Peulen O; Rademaker G; Gabriel M; Monseur C; Charloteaux B; Verbeke L; van Laere S; Roncarati P; Herfs M; Lambert C; Scheijen J; Schalkwijk C; Colige A; Caers J; Delvenne P; Turtoi A; Castronovo V; Bellahcène A
Breast Cancer Res; 2019 Jan; 21(1):11. PubMed ID: 30674353
[TBL] [Abstract][Full Text] [Related]
15. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
Fukazawa H; Noguchi K; Murakami Y; Uehara Y
Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
[TBL] [Abstract][Full Text] [Related]
16. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
[TBL] [Abstract][Full Text] [Related]
17. Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs).
Lin L; Kuhn C; Ditsch N; Kolben T; Czogalla B; Beyer S; Trillsch F; Schmoeckel E; Mayr D; Mahner S; Jeschke U; Hester A
Breast Cancer Res; 2021 Apr; 23(1):45. PubMed ID: 33849622
[TBL] [Abstract][Full Text] [Related]
18. Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer progression by regulating the EGFR/MEK/ERK signaling pathway.
Zhang X; Gao D; Fang K; Guo Z; Li L
Cancer Lett; 2019 Mar; 444():105-115. PubMed ID: 30583076
[TBL] [Abstract][Full Text] [Related]
19. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.
Verma A; Guha S; Wang H; Fok JY; Koul D; Abbruzzese J; Mehta K
Clin Cancer Res; 2008 Apr; 14(7):1997-2005. PubMed ID: 18381937
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of ecotropic viral integration site 2A indicates a poor prognosis and promotes osteosarcoma evolution through activating MEK/ERK pathway.
Li S; Yang F; Yang YK; Zhou Y
J Recept Signal Transduct Res; 2019 Aug; 39(4):368-372. PubMed ID: 31774019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
